The short answer — and why it depends on your joint

For the right patient, yes — cartilage repair can delay a knee replacement, sometimes by many years. The important qualification is that 'the right patient' is doing real work in that sentence. The benefit is not universal, and what determines it is the condition of the joint rather than symptoms alone.

The underlying biology explains why. Articular cartilage has no direct blood supply, which means it has essentially no capacity to repair itself once damaged. A small defect does not simply stabilise; lesions larger than roughly 1 cm² tend to propagate over time, progressively thinning the joint surface and accelerating the pathway towards osteoarthritis and eventual joint replacement. Intervening early — before surrounding cartilage deteriorates — is what gives repair procedures their best chance of holding.

The strongest case for delay sits with younger, active patients who have a single, focal lesion and healthy cartilage in the rest of the joint. Those with widespread or diffuse damage are less likely to benefit, and in those cases replacement often remains the more reliable route. Equally, while the delaying effect is well-grounded in clinical evidence, it has not yet been expressed as a precise number of years in high-quality trials — most studies measure pain and function rather than time-to-replacement as a primary endpoint.

Which patients are the strongest candidates

Several variables determine whether repair is realistic — and working through them honestly is more useful than a blanket yes or no.

Age and activity level. Cartilage repair is best supported by evidence in patients typically under 50 who remain physically active. Younger, higher-demand patients gain the most from preserving their own joint surface, and the biological environment in younger tissue tends to support better healing responses.

Lesion pattern — focal versus diffuse. If your damage is confined to one clearly demarcated area with healthy cartilage around it, you are in the best position for repair. Multiple lesions scattered across a compartment, or diffuse thinning across the joint surface, respond far less predictably — and in those cases the balance shifts towards replacement.

Cartilage grade. ICRS (or Outerbridge) grading describes how deeply a lesion penetrates. Grade III lesions — extending more than half the cartilage depth — are still within the scope of repair in well-selected patients. Grade IV lesions, where damage has broken through to the underlying subchondral bone, sit at the outer limit of indication and require careful assessment before committing to a restorative approach.

Alignment. A knee that runs in significant varus (bow-legged) or valgus (knock-kneed) concentrates load unevenly across the joint. Cartilage repair in a malaligned knee is unlikely to hold unless alignment is corrected at the same time, often through an osteotomy procedure.

Surrounding joint health. Substantial pre-existing osteoarthritis in the wider compartment tips the balance towards replacement rather than repair, regardless of how focal the primary lesion appears.

Patients who fall outside these criteria are not being denied a solution — they are being directed to a more appropriate one.

Matching the repair technique to the defect

The size of the defect is the single biggest factor in choosing a repair technique — not because surgeons are working through a checklist, but because different tissue-engineering strategies have hard biological limits.

Small defects (under 2 cm²)

For contained focal lesions in this range, two single-stage surgical options are well supported. OATS (osteochondral autograft transfer / mosaicplasty) transplants a cylinder of the patient's own bone and cartilage from a low-load area of the knee into the defect, producing hyaline-like cartilage at the repair site. The trade-off is donor-site morbidity — a secondary wound where the graft was harvested. AMIC (autologous matrix-induced chondrogenesis) combines marrow stimulation with a collagen matrix scaffold, bridging the gap between simple microfracture and cell-based techniques, in a single operative stage.

Larger defects (2–10 cm²)

MACI (matrix-induced autologous chondrocyte implantation) is the preferred cell-based option at this scale. The SUMMIT RCT provides the head-to-head evidence for defects of 3 cm² or larger, and the detail is covered in the following section on long-term outcomes.

The largest and posttraumatic defects (above ~10 cm²)

At this scale, fresh osteochondral allograft (OCA) — composite donor tissue containing both cartilage and underlying bone — is the only reconstructive option. Viable donor chondrocytes survive for only around 28 days after procurement, which restricts the procedure to centres with direct tissue-bank access and rapid implantation pathways.

A note on microfracture

Microfracture was historically the default first-line treatment for smaller defects. Current evidence has significantly qualified that position: the fibrocartilage it produces tends to break down within two to three years, and repeated marrow stimulation can disrupt the subchondral bone plate in ways that compromise future repair attempts. It is acknowledged here for historical context rather than as a modern first choice.

When alignment must be corrected first

If a varus or valgus deformity is concentrating load unevenly — a point already noted in candidate selection — a corrective osteotomy (HTO or DFO) needs to run alongside any cartilage procedure. Repairing tissue in a mechanically hostile environment substantially reduces the chance of durable benefit.

What the long-term evidence actually shows

Three separate long-term datasets converge on the same conclusion: cartilage repair, in appropriately selected patients, produces durable benefit that extends well beyond the short term.

The most cited cell-based result is the Minas et al. study recognised with the John Insall Award in 2014 — a minimum 10-year follow-up of autologous chondrocyte implantation confirming that outcomes held in patients who had been selected carefully at the outset. A decade is a meaningful threshold; it is long enough to distinguish genuine durability from short-term pain relief that erodes after a few years.

The SUMMIT RCT, referenced in the previous section for its headline KOOS figures, carries a distinct significance here: it remains the only randomised controlled trial to pit MACI directly against microfracture in larger defects. Those improvements in pain and function scores represent something concrete for patients — better daily mobility and lower pain at the critical mid-term timepoints, not merely a numerical shift on a questionnaire scale.

A 16-year follow-up dataset in osteochondritis dissecans adds a further dimension: surgical restoration produced significantly lower rates of osteoarthritis than fragment excision alone. That finding directly supports the case for biological reconstruction over debridement when the joint surface can be preserved.

Where current evidence is less complete is in the primary endpoint most patients want answered. Most trials measure KOOS scores, VAS pain ratings, and return to sport — not the calendar date of eventual knee replacement. In well-selected cases, repair justifiably delays the need for a new joint; what the evidence cannot yet state with precision is exactly how many years that delay amounts to in a rigorously controlled trial. Claims of a specific figure should be read with that in mind.

Minimally invasive options that extend the preservation window

Not every patient presenting with a focal cartilage defect is ready for surgical reconstruction. For those at an earlier stage — meaningful symptoms, a contained lesion, but not yet at the threshold for a theatre-based procedure — a growing range of outpatient interventions can extend the preservation window before replacement becomes necessary.

ChondroFiller injection works as an injectable collagen scaffold placed under ultrasound guidance in an outpatient setting. Rather than transplanting cells or tissue, it provides a structural matrix into which the patient's own progenitor cells migrate and remodel over roughly 12 months — a process described as matrix-induced chondrogenesis. Published clinical series report meaningful improvements in pain and function scores for focal defects up to approximately 3 cm², with some evidence extending that to 6 cm². Because the approach is single-stage and avoids general anaesthesia, the procedural burden is substantially lower than cell-based techniques such as MACI.

For KL grade III–IV patients weighing an early joint replacement, a combined ChondroFiller and Arthrosamid protocol can address two distinct problems in one visit: the ChondroFiller scaffold targets the cartilage defect through the regenerative pathway, while Arthrosamid — a non-regenerative polyacrylamide hydrogel — addresses the joint environment and synovial lining. They act on different tissue targets and should not be treated as interchangeable or blended into a single category.

NanoACi represents an emerging single-stage injectable cell therapy. Long-term comparative data is not yet available, and it is better understood as a next-generation development than an established standard.

The same honest caveat applies across this entire minimally invasive tier: head-to-head trials against MACI or osteochondral allograft at equivalent defect sizes have not yet been conducted. These options genuinely expand what is available to patients before surgery becomes necessary — they do not replace established surgical repair for larger or more severe lesions.

How the repair-or-replace decision is made at MSK Doctors

The practical next step for most patients is a structured assessment that works through the same variables the evidence highlights: defect size and grade, the condition of surrounding cartilage and subchondral bone, alignment, and how the joint is loaded during everyday movement.

Pre-operative MRI — including compositional sequences such as T2 mapping — is the gold-standard tool for characterising all of those factors before any repair decision is made. Where load distribution or gait pattern is relevant to the decision (particularly in patients where malalignment may need correction alongside repair), objective biomechanical assessment using AI-powered markerless motion capture — MAI Motion®, UKCA/MHRA-registered — adds measurable data that clinical examination alone cannot provide.

Consultant-led assessment at MSK Doctors is available without a GP referral and without NHS-style waiting lists. Non-London patients are seen primarily at the Sleaford Regeneration Hub in Lincolnshire, which houses an Open MRI scanner, and at the Grantham centre. London-based patients can access equivalent cartilage expertise through the London Cartilage Clinic.

To arrange an assessment, visit mskdoctors.com.